Introduction
============

Extranodal natural killer-T cell lymphoma (ENKL) is a subtype of non-Hodgkin lymphoma ([@b1-mco-0-0-1067]), occurring more frequently in Asia compared with Western countries ([@b2-mco-0-0-1067]). According to a recent survey, ENKL is the second most common extranodal lymphoma subtype in China after large B-cell lymphoma ([@b3-mco-0-0-1067]). ENKL is very aggressive, characteristically damaging vessels and surrounding tissues and initiating cytotoxic responses. The mean incidence is in middle age (43.1 years) ([@b3-mco-0-0-1067]). Over half of patients present with local symptoms, and the nasal region is the most common primary site ([@b4-mco-0-0-1067]). ENKL may also involve the skin, gastrointestinal tract, lung and liver, while soft tissue involvement is rare ([@b5-mco-0-0-1067]). The majority of the patients have B symptoms, whereas bone marrow involvement is rare ([@b4-mco-0-0-1067]). Patients typically have evidence of Epstein-Barr virus infection ([@b6-mco-0-0-1067]).

There is a range of reported treatments for ENKL, with varied efficacy. A Chinese report of 58 patients with early-stage disease ([@b7-mco-0-0-1067]) indicated that primary radiotherapy may increase the progression-free survival and 3-year overall survival. Chauchet *et al* ([@b8-mco-0-0-1067]) analyzed the optimal therapeutic options and factors affecting prognosis in 36 European patients with ENKL and concluded that early radiotherapy, concomitantly or sequentially with chemotherapy, may improve patient outcomes. However, Ma *et al* ([@b9-mco-0-0-1067]), in agreement with a recent meta-analysis ([@b10-mco-0-0-1067]), reported that the 5-year survival rates were not different between the radiotherapy and chemoradiotherapy groups in their study of 64 patients with early-stage nasal-type ENKL (57.9 and 61.5% respectively, P=0.47). The 2015 National Comprehensive Cancer Network (NCCN) guidelines ([@b11-mco-0-0-1067]) recommend several treatment regimens for ENKL for patients with different clinical characteristics. Chemotherapy and radiotherapy are currently the main options, but their efficacy remains controversial among different studies and in different countries.

The present study was conducted to retrospectively analyze the clinical characteristics and compare different treatment regimens for ENKL by investigating the survival of 69 patients with this disease, with the aim to summarize the experience of treating ENKL in clinical practice and provide a reference for future clinical treatment.

Patients and methods
====================

### Inclusion criteria

The inclusion criteria of our study were as follows: Pathologically confirmed ENKL with complete pathological data and absence of comorbid conditions. Follow-up data were complete, including physical examination, laboratory and imaging results, treatments administered and dates of recurrence and death.

### Objective

This retrospective study was conducted at The First Affiliated Hospital of the Medical College of Xi\'an Jiaotong University (Xi\'an, China), and included 69 ENKL patients who were clinicopathologically diagnosed between 2004 and 2015. Pathological diagnosis was made according to the World Health Organization classification criteria ([@b12-mco-0-0-1067]). Pathological data were collected from the Pathology Department of our hospital. The certain risk factors of ENKL were evaluated according to the 2015 NCCN guidelines, along with the International Prognostic Index (IPI), including age, serum lactate dehydrogenase (LDH), B symptoms, lymph node status, Ann Arbor stage, Eastern Cooperative Oncology Group performance status (ECOG PS) and number of extranodal sites.

### Statistical analysis

Statistical analyses were performed using SPSS 21.0 statistical software (IBM Corp., Armonk, NY, USA) and GraphPad Prism software (GraphPad Software, San Diego, CA, USA). Clinical factors were estimated using Kaplan-Meier analysis and the log-rank test was used to assess significance of survival. The Chi-square test was used to compare the clinical factors between the radiotherapy and non-radiotherapy groups. Cox regression models were used for multivariate survival analysis. P-values \<0.05 were considered to indicate statistically significant differences.

Results
=======

### Clinical characteristics and treatment regimens

The study included 50 men and 19 women, and 17 patients were aged ≥60 years at diagnosis. The nasal cavity was the most common primary site (58.0%). A total of 15 patients (21.7%) had ECOG PS scores ≥2, and 14 patients (20.3%) had IPI scores of 3--5. A total of 44 (63.8%) and 25 (36.2%) patients had Ann Arbor stage I/II and III/IV disease, respectively. B symptoms were present at diagnosis in 33 patients (47.8%), and 33 patients also had lymph node involvement, while only 3 patients had bone marrow involvement. The LDH levels were increased in 33 patients.

In our study, 5 patients underwent surgery, 7 underwent radiotherapy, 30 received chemotherapy alone and 29 received chemoradiotherapy. Chemotherapy combined with autologous hematopoietic stem cell transplantation (HSCT) was administered to 2 patients. In addition, 3 patients only received palliative care due to their poor health status. The initial chemotherapy regimens included cyclophosphamide, adriamycin, vincristine and prednisone (CHOP) in 36 cases, etoposide + CHOP (ECHOP) in 6 cases, gemcitabine + platinum (GP) in 4 cases, dexamethasone, methotrexate, ifosfamide, L-asparaginase and etoposide (SMILE) in 4 cases, and other regimens (e.g., L-asparaginase-based regimens) in the remaining 9 cases. Locoregional radiotherapy with a dose of 45--62 Gy was administered to the patients who received radiotherapy.

### Univariate survival analysis

All the patients were followed until death or through to April 20, 2015 (deadline date of our study), with a median follow-up of 38 months (range, 1--132 months). The median OS (mOS) was 96 months for all patients, with a 5-year survival rate of 68.0%. However, these data were obviously below average for patients with extranasal primary tumors (63 months, 43.4%), ECOG score ≥2 (10 months, 0%), IPI score 3--5 (9 months, 21.4%), stage III/IV disease (20 months, 43.6), presence of B symptoms (70 months, 55.7%), lymph node involvement (63 months, 57.4%), and those not receiving radiotherapy (63 months, 55.9%) ([Table I](#tI-mco-0-0-1067){ref-type="table"}).

The following characteristics were found to indicate poor survival: Primary tumors arising outside the nasal region (HR=0.33, P=0.0079), ECOG score ≥2 (HR=0.01, P\<0.0001), IPI score 3--5 (HR=0.02, P\<0.0001), stage III/IV disease (HR=0.16, P\<0.0001), presence of B symptoms (HR=2.72, P=0.0183), lymph node involvement (HR=0.34, P=0.0084) and absence of radiotherapy (HR=0.30, P=0.0041 ([Table I](#tI-mco-0-0-1067){ref-type="table"}).

### Comparison between radiotherapy and non-radiotherapy groups

A comparison between the radiotherapy and non-radiotherapy groups by Chi-square tests indicated that patients who received radiotherapy had higher rates of ECOG 0--1 (88.89 vs. 66.67%, P=0.0254), IPI 0--2 (91.67 vs. 66.67%, P=0.0099), Ann Arbor stage I/II disease (75.00 vs. 51.51%, P=0.0426), absence of B symptoms (63.89 vs. 39.39%, P=0.0419), normal serum LDH level (63.89 vs. 39.39%, P=0.0419), and absence of lymph node involvement (63.89 vs. 39.39%, P=0.0419) ([Table II](#tII-mco-0-0-1067){ref-type="table"}). Therefore, the survival results of the two groups cannot be compared directly.

### Multivariate survival analysis

Cox regression multivariate analysis yielded the following significant prognostic factors for OS in patients with ENKL: ECOG score (HR=9.537, P\<0.0001), disease stage (HR=5.500, P=0.006), IPI (HR=3.650, P=0.022), presence of B symptoms (HR=3.070, P=0.039) and radiotherapy (HR=2.970, P=0.046), indicating that these factors were independently associated with survival of ENKL ([Table III](#tIII-mco-0-0-1067){ref-type="table"}).

### Analysis of the effect of diverse therapies on survival

To further assess the effect of different regimens, the patients were divided into subgroups by different treatment regimens, different stages and different primary sites. Considering that the radiotherapy group included patients who had received radiotherapy alone as well as chemoradiotherapy, survival was analyzed among the chemoradiotherapy, chemotherapy and radiotherapy groups. The mOS of patients was 118, 63 and 132 months, respectively, and the corresponding 5-year survival rates were 77.5, 45.0 and 83.3%, respectively (P=0.0412) ([Fig. 1A](#f1-mco-0-0-1067){ref-type="fig"}); however, no statistically significant difference was found between the chemoradiotherapy and radiotherapy groups (HR=1.534, P=0.6371) ([Fig. 1B](#f1-mco-0-0-1067){ref-type="fig"}). These results indicated that the effects were different among the three treatment regimens, but chemoradiotherapy did not provide a significant advantage over radiotherapy. Since the chemotherapy regimens were mainly anthracycline-based, the patients were divided into the anthracycline-based and non-anthracycline based regimen groups; however, no significant differences were found between these groups in terms of mOS and 5-year survival rates ([Table IV](#tIV-mco-0-0-1067){ref-type="table"}).

The survival of patients was then compared by different stages, different primary sites and different treatment regimens. The results revealed a difference between the radiotherapy and non-radiotherapy groups for patients with extranasal-type stage III/IV disease. The mOS for patients with extranasal-type stage III/IV disease in the radiotherapy and non-radiotherapy groups was 81.5 and 12 months, respectively, and the 5-year survival rates differed significantly between the groups (100 vs. 0%, respectively; P=0.0229). No significant differences were found between other groups in terms of mOS and 5-year survival rates. Our data demonstrated that patients with advanced disease may also benefit from radiotherapy ([Table IV](#tIV-mco-0-0-1067){ref-type="table"}).

Discussion
==========

ENKL is a rare extranodal malignancy with poor prognosis. This retrospective study analyzed the clinical characteristics of patients with ENKL. In agreement with previous studies ([@b2-mco-0-0-1067],[@b13-mco-0-0-1067]), our data demonstrated that ECOG score, stage, IPI, presence of B symptoms and treatment with radiotherapy were independently associated with the survival of ENKL. However, the LDH level did not exhibit an independent association with survival, which differed from the results of other studies ([@b1-mco-0-0-1067],[@b8-mco-0-0-1067]), despite the fact that the mOS of patients with elevated serum LDH was below average (70 vs. 96 months) ([Table I](#tI-mco-0-0-1067){ref-type="table"}). A larger sample size is required to further investigate this point.

Radiotherapy is one of the most important treatments for ENKL and has been confirmed in previous studies to improve patient outcomes ([@b7-mco-0-0-1067],[@b8-mco-0-0-1067]). Consistent with these prior reports, our results demonstrated that radiotherapy was able to increase the mOS and 5-year survival rate (132 months, 77.9% vs. 63 months, 55.9%, P=0.0041) of ENKL ([Table I](#tI-mco-0-0-1067){ref-type="table"}) and was one of the independent prognostic factors for survival ([Table III](#tIII-mco-0-0-1067){ref-type="table"}). However, the majority of the studies on ENKL evaluated nasal-type and early-stage disease ([@b14-mco-0-0-1067]), while few focused on extranasal and late-stage disease. In our study, we also observed that, for patients with stage III/IV disease, the mOS and 5-year survival rate of those receiving radiotherapy were 96 months and 80.0%, respectively, which were more favorable compared with those of patients not receiving radiotherapy (12 months and 30.3%, respectively), although this difference did not quite reach statistical significance with the number of investigated patients (P=0.0656). In the subgroup analysis stratified by stage and primary site, a statistical difference was observed in the stage III/IV extranasal subgroup between the radiotherapy and non-radiotherapy groups (P=0.0229), but the samples were relatively small and unbalanced ([Table IV](#tIV-mco-0-0-1067){ref-type="table"}). Taken together, our results indicated that patients with advanced disease may also benefit from radiotherapy, although further studies are required to support our findings.

Recently, a meta-analysis of 8 clinical studies compared the efficacy of chemoradiotherapy and chemotherapy for treating early-stage ENKL ([@b10-mco-0-0-1067]), concluding that chemoradiotherapy did not provide a significant advantage over radiotherapy for early-stage nasal-type ENKL. Similarly, we observed that patients in the radiotherapy group achieved a significantly longer mOS and higher 5-year survival rates compared with those in the chemoradiotherapy and the chemotherapy groups (132 months, 83.3% vs. 118 months, 77.5% vs. 63 months, 45.0%, respectively; P=0.0412) ([Fig. 1A](#f1-mco-0-0-1067){ref-type="fig"}). In our study, however, the mOS and 5-year survival rates were not statistically different in the I/II nasal-type subgroups, possibly because the number of patients with stage I/II nasal-type disease was small (n=31). A recent study ([@b15-mco-0-0-1067]) suggested that, unlike patients with stage I nasal-type disease, who may achieve favorable outcomes when treated with radiotherapy alone, patients with stage II disease or with paranasal involvement should be treated with systemic therapy. Thus, radiotherapy may still be the optimal choice, but whether patients with unfavorable prognosis should be treated with chemotherapy and the optimal chemotherapy regimens require further investigation.

ENKL is often resistant to anthracycline-based chemotherapy ([@b1-mco-0-0-1067]). Although the prognosis of some patients was improved by non-anthracycline-based chemotherapy, the prognosis of patients with advanced disease remains poor ([@b13-mco-0-0-1067]). Au *et al* ([@b16-mco-0-0-1067]) investigated 136 patients with ENKL and did not find differences between the nasal and extranasal groups in subgroups treated with anthracycline-based chemotherapy, radiotherapy, or a combination of the two. Similarly, in our study, 42 of the 69 patients were administered an anthracycline-based regimen as first-line therapy and the mOS and 5-year survival rates did not differ between those treated with or without radiotherapy.

Obama ([@b17-mco-0-0-1067]) reported that, for radiotherapy-resistant disease, chemoradiotherapy, including the topoisomerase inhibitors etoposide (VP-16) and irinotecan (CPT-11), may be a therapeutic option. The present study included only 6 cases treated with ECHOP, among which 5 received chemoradiotherapy; thus, more data are required to evaluate this type of treatment. SMILE has been reported as a potential first-line chemotherapy regimen for ENKL patients ([@b5-mco-0-0-1067],[@b18-mco-0-0-1067],[@b19-mco-0-0-1067]). A phase II study ([@b20-mco-0-0-1067]) also demonstrated that SMILE chemotherapy may be a choice for patients with stage IV ENKL with relapsed or refractory disease. The present study included 4 patients treated with the SMILE chemotherapy regimen, but only 1 received sequential radiotherapy. That patient received only 2 cycles of chemotherapy, due to myelosuppression. The SMILE regimen may achieve better outcomes for ENKL, but it is associated with a high risk of myelosuppression during the long treatment period. Furthermore, its clinical value and ability to be used in combination with radiotherapy remain uncertain.

HSCT is a potential therapeutic option, allowing some patients to achieve remission ([@b21-mco-0-0-1067]). The present study included only 2 patients who had been treated with HSCT, and they have achieved 30 and 34 months of remission. However, further investigation is required to identify more effective therapeutic options for this disease.

In conclusion, ECOG PS score, disease stage, IPI, presence of B symptoms and treatment with radiotherapy were the independent prognostic factors of OS in patients with ENKL. Radiotherapy achieved better outcomes, but no difference was observed between chemoradiotherapy and radiotherapy. Patients with advanced disease may also benefit from radiotherapy.

The present study was supported by the Natural Science Foundation of China (grant no. 81172169).

![Comparison of overall survival (OS) among patients who received chemoradiotherapy, those who received chemotherapy alone and those who received radiotherapy alone using the Kaplan-Meier method. (A) The survival curves of the chemoradiotherapy vs. chemotherapy vs. radiotherapy groups were significantly different (P=0.0412). (B) The survival curves of the chemoradiotherapy vs. radiotherapy groups were not significantly different (P=0.6371).](mco-05-06-0750-g00){#f1-mco-0-0-1067}

###### 

Univariate analysis of overall survival by clinical factors (n = 69).

                                  Survival rate (%)                                                                                    
  ------------------------- ----- ------------------- -------- ------ --------------------------------------------------------- ------ -------------
  Gender                                                                                                                               
  Men                       50    81.9                71.1       96   0.5698                                                    1.31   0.51--3.37
  Women                     19    73.3                58.8     118                                                                     
  Age (years)                                                                                                                          
  ≤60                       52    80.7                65.4       96   0.8103                                                    1.13   0.43--2.96
  \>60                      17    76.0                76.0     87                                                                      
  Primary site                                                                                                                         
  Nasal                     40    84.8                81.5     132    0.0079^[a](#tfn1-mco-0-0-1067){ref-type="table-fn"}^      0.33   0.14--0.75
  Extranasal                29    72.4                43.4       63                                                                    
  ECOG score                                                                                                                           
  0--1                      54    92.6                83.8     132    \< 0.0001^[a](#tfn1-mco-0-0-1067){ref-type="table-fn"}^   0.01   0.003--0.03
  ≥ 2                       15    33.3                0          10                                                                    
  IPI                                                                                                                                  
  0--2                      55    90.8                80.2     132    \< 0.0001^[a](#tfn1-mco-0-0-1067){ref-type="table-fn"}^   0.02   0.006--0.08
  3--5                      14    35.7                21.4       9                                                                     
  Ann Arbor stage                                                                                                                      
  I/II                      44    95.5                82.5     132    \< 0.0001^[a](#tfn1-mco-0-0-1067){ref-type="table-fn"}^   0.16   0.06--0.39
  III/IV                    25    52.0                43.6       20                                                                    
  B symptoms                                                                                                                           
  Yes                       33    63.5                55.7       70   0.0183^[a](#tfn1-mco-0-0-1067){ref-type="table-fn"}^      2.72   1.19--6.24
  No                        36    94.3                79.1       96                                                                    
  Serum LDH (U/L)                                                                                                                      
  Normal                    36    83.2                69.9     132    0.1861                                                    0.58   0.26--1.30
  Elevated                  33    75.6                65.7       70                                                                    
  Bone marrow involvement                                                                                                              
  Yes                         3   66.7                66.7     132    0.8552                                                    1.22   0.14--10.98
  No                        66    80.1                68.1       96                                                                    
  Lymph node involvement                                                                                                               
  Yes                       33    66.7                57.4       63   0.0084^[a](#tfn1-mco-0-0-1067){ref-type="table-fn"}^      0.34   0.15--0.76
  No                        36    91.7                75.3     132                                                                     
  Surgery                                                                                                                              
  Yes                         5   100.0               100.0      95   0.1413                                                    0.33   0.08--1.45
  No                        64    77.9                65.5       96                                                                    
  Radiotherapy                                                                                                                         
  Yes                       36    94.3                77.9     132    0.0041^[a](#tfn1-mco-0-0-1067){ref-type="table-fn"}^      0.30   0.13--0.68
  No                        33    64.7                55.9       63                                                                    
  Chemotherapy                                                                                                                         
  Yes                       59    81.3                69.8       96   0.5267                                                    0.67   0.20--2.29
  No                        10    70.0                58.3     132                                                                     
  HSCT                                                                                                                                 
  Yes                         2   100.00              100.00     34   0.4089                                                    0.35   0.03--4.23
  No                        67    78.9                67.2       96                                                                    
  All patients              69    79.6                68.0       96                                                                    

P\<0.05. mOS, median overall survival; HR, hazard ratio; CI, confidence interval; ECOG, Eastern Cooperative Oncology Group; IPI, international prognostic index; LDH, lactate dehydrogenase; HSCT, hematopoietic stem cell transplantation.

###### 

Comparison of clinical factors between different treatment groups with the Chi-square test.

  Clinical factors          Radiotherapy n=36 (%)   Non-radiotherapy n=33(%)   P-value
  ------------------------- ----------------------- -------------------------- ------------------------------------------------------
  Gender                                                                       
  Men                       26 (72.22)              24 (72.73)                 0.9626
  Women                     10 (27.78)              9 (27.27)                  
  Age (years)                                                                  
  ≤ 60                      27 (75.00)              25 (75.76)                 0.9418
  \>60                      9 (25.00)               8 (24.24)                  
  Primary site                                                                 
  Nasal                     24 (66.67)              16 (48.48)                 0.1264
  Extranasal                12 (33.33)              17 (51.51)                 
  ECOG score                                                                   
  0--1                      32 (88.89)              22 (66.67)                 0.0254^[a](#tfn2-mco-0-0-1067){ref-type="table-fn"}^
  ≥ 2                       4 (11.11)               11 (33.33)                 
  IPI                                                                          
  0--2                      33 (91.67)              22 (66.67)                 0.0099^[a](#tfn2-mco-0-0-1067){ref-type="table-fn"}^
  3--5                      3 (8.33)                11 (33.33)                 
  Ann Arbor stage                                                              
  I/II                      27 (75.00)              17 (51.51)                 0.0426^[a](#tfn2-mco-0-0-1067){ref-type="table-fn"}^
  III/IV                    9 (25.00)               16 (48.48)                 
  B symptoms                                                                   
  Yes                       13 (36.11)              20 (60.60)                 0.0419^[a](#tfn2-mco-0-0-1067){ref-type="table-fn"}^
  No                        23 (63.89)              13 (39.39)                 
  Serum LDH                                                                    
  (U/l)                                                                        
  Normal                    23 (63.89)              13 (39.39)                 0.0419^[a](#tfn2-mco-0-0-1067){ref-type="table-fn"}^
  Elevated                  13 (36.11)              20 (60.60)                 
  Bone marrow involvement                                                      
  Yes                       1 (2.78)                2 (6.06)                   0.5042
  No                        35 (97.22)              31 (93.94)                 
  Lymph node involvement                                                       
  Yes                       13 (36.11)              20 (60.60)                 0.0419^[a](#tfn2-mco-0-0-1067){ref-type="table-fn"}^
  No                        23 (63.89)              13 (39.39)                 
  Surgery                                                                      
  Yes                       4 (11.11)               1 (3.03)                   0.1959
  No                        32 (88.89)              32 (96.97)                 
  Chemotherapy                                                                 
  Yes                       29 (72.22)              30 (90.91)                 0.2223
  No                        7 (19.44)               3 (9.09)                   
  HSCT                                                                         
  Yes                       0 (0.0)                 2 (6.06)                   0.1339
  No                        36 (100.00)             31 (93.94)                 

P\<0.05. ECOG, Eastern Cooperative Oncology Group; IPI, international prognostic index; LDH, lactate dehydrogenase; HSCT, hematopoietic stem cell transplantation.

###### 

Multivariate analysis of survival with Cox proportional hazards model.

                  95% CI for Exp (B)                                                                                               
  --------------- -------------------- ------- --------- --- ----------------------------------------------------- ------- ------- ---------
  Age             0.025                0.015     2.800   1   0.094                                                 1.026   0.996     1.057
  ECOG PS score   2.255                0.598   14.220    1   0.000^[a](#tfn3-mco-0-0-1067){ref-type="table-fn"}^   9.537   2.954   30.796
  Stage           1.705                0.614     7.702   1   0.006^[a](#tfn3-mco-0-0-1067){ref-type="table-fn"}^   5.500   1.650   18.334
  IPI             1.295                0.564     5.276   1   0.022^[a](#tfn3-mco-0-0-1067){ref-type="table-fn"}^   3.650   1.209   11.016
  B symptoms      1.122                0.545     4.240   1   0.039^[a](#tfn3-mco-0-0-1067){ref-type="table-fn"}^   3.070   1.056     8.928
  Radiotherapy    1.089                0.546     3.969   1   0.046^[a](#tfn3-mco-0-0-1067){ref-type="table-fn"}^   2.970   1.018     8.667

P\<0.05. CI, confidence interval; B, coefficient of covariates; SE, standard error; df, degree of freedom; sig, significance; Exp (B), relative risk; ECOG PS, Eastern Cooperative Oncology Group performance status; IPI, international prognostic index.

###### 

Subgroup survival analysis.

                 Nasal   Extranasal   Total                                                                                                            
  -------------- ------- ------------ ------- -------- ----- ------ ------- ------------------------------------------------------ ----- ------ ------ ------------------------------------------------------
  Stage I/II                                                                                                                                           
    CT           12      70           75.0    0.1003     5   90.5   100.0   0.5817                                                 17      70   61.7   0.3243
    RT/CT        19      132          87.8               8   118    62.5                                                           27    132    79.4   
    A            18      99           82.3    0.8836     9   118    75.2    0.2945                                                 27    118    80.3   0.3821
    Non-A          7     67           85.7               3   95     100.0                                                          10      95   90.0   
  Stage III/IV                                                                                                                                         
    CT             4     32           0       0.7472     9   12     0       0.0229^[a](#tfn4-mco-0-0-1067){ref-type="table-fn"}^   13      12   30.8   0.0656
    RT/CT          5     54           0                  4   81.5   100                                                              9     96   80.0   
    A              7     54           0       0.4692     8   96     51.9    0.7137                                                 15      96   54.5   0.5927
    Non-A          2     27.5         0                  5   24     0                                                                7     24   0      
  Total                                                                                                                                                
    CT           16      70           68.8    0.1133   14    43.5   50.0    0.0543                                                 30      63   45.0   0.0102^[a](#tfn4-mco-0-0-1067){ref-type="table-fn"}^
    RT/CT        24      132          81.9             12    96     72.9                                                           36    132    78.6   
    A            25      99           77.9    0.3792   17    96     51.3    0.5319                                                 42      96   69.9   0.6902
    Non-A          9     67           66.7               8   71     50.0                                                           17      95   64.7   

P\<0.05. mOS, median overall survival; CT, chemotherapy alone; RT/CT, radiotherapy with or without chemotherapy; A, anthracycline-based regimen; Non-A, non-anthracycline-based regimen.
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